



WATCHMAN Referral Form

PATIENT NAME	DOR
PHONE NUMBER	EMAIL
DRUG REGIMEN	CHA ₂ DS ₂ -VASc
CHA ₂ DS ₂ -VASc of ≥2 (or CHA ₂ DS ₂ -VASc of ≥3 for Patient is suitable for short-term warfa	e and is recommended for oral anticoagulation (OAC) Medicare patients). See table on back page. Irin therapy but deemed unable to take long-term OAC seek a non-pharmacologic alternative to warfarin.
History of bleeding or increased bleHistory or risk of fallsDocumented poor compliance with	eeding risk (See HAS-BLED table on back page.) OAC therapy
 Inability or difficulty maintaining the Increased bleeding risk not reflecte (e.g., thrombocytopenia, cancer, or systemic anticoagulation) 	
Occupation/lifestyle that puts patients Severe renal failure	nt at an increased bleeding risk
Other situations for which OAC is in	nappropriate
Urug or medication regimen not coi	mpatible with oral anticoagulant therapy
REFERRING DR.	
PHONE NUMBER	FMAII





CHA₂DS₂-VASc Score (Stroke Risk)^a

	Condition	Points
С	Congestive heart failure	1
Н	Hypertension (SBP > 160)	1
Α	Age ≥ 75 years	2
D	Diabetes mellitus	1
S ₂	Prior stroke, TIA, or thromboembolism	2
V	Vascular disease (PAD, MI)	1
А	Age 65-74 years	1
Sc	Sex category (Female)	1
Total Points		

Score	Yearly Stroke Risk (%)		
	No Warfarin	With Aspirin ^b	With Warfarin ^b
0	0	0	0
1	1.3	1.0	0.5
2	2.2	1.8	0.8
3	3.2	2.6	1.1
4	4.0	3.2	1.4
5	6.7	5.4	2.3
6	9.8	7.8	3.4

HAS-BLED Score (Bleeding Risk with Warfarin)^c

	Condition	Points	
Н	Hypertension	1	
Α	Abnormal renal/liver fuction (1 pt each)	1 or 2	
S	Stroke	1	
В	Bleeding history or disposition	1	
L	Labile INR	2	
Е	Elderly (e.g. age > 65 years)	1	
D	Current drugs (medication) or alcohol use (1 pt each)	1 or 2	
Total	Total Points		

Score	Yearly Major Bleeding Risk (%)*
0	1.13
1	1.02
2	1.88
3	3.74
4	8.70
5+	12.5

References

a. CHA₂DS₂-VASc: *Chest*. 2010;137(2):263-272.

b. Warfarin Stroke Reduction: Ann Intern Med. 2007;146:857-867.

c. HAS-BLED: Chest. 2010;138(5):1093-1100.

*Major Bleed = ICH or bleeding resulting in a hospitalization, a hemoglobin drop > 2 g/dL, or a blood transfusion. NOTE: A high HAS-BLED score is ≥3.

Formal Shared Decision Making

The patient must have a formal shared decision making interaction with an independent, non-interventional physician using an evidence-based decision tool on oral anticoagulation in patients with NVAF prior to LAAC. Additionally, the shared decision making interaction must be documented in the medical record. THIS IS NOT A FORMAL SHARED DECISION MAKING DOCUMENT AND CANNOT BE USED FOR RECORDING THE SHARED DECISION MAKING INTERACTION.